# Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)

Study · id `cardio:ct-nct01515228` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01515228](<https://clinicaltrials.gov/study/NCT01515228>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01515228

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 291 participants.

## Technical summary

Registry record NCT01515228. Randomized; no masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 291 participants (enrolled count; ClinicalTrials.gov record NCT01515228, source copy `cardio:ctgov-nct01515228-2015-01-09`, retrieved 2026-10-26)
- Start date: 2012-01 (registry gives no type) (ClinicalTrials.gov record NCT01515228, source copy `cardio:ctgov-nct01515228-2015-01-09`, retrieved 2026-10-26)
- Primary completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01515228, source copy `cardio:ctgov-nct01515228-2015-01-09`, retrieved 2026-10-26)
- Completion: 2015-01 (actual) (ClinicalTrials.gov record NCT01515228, source copy `cardio:ctgov-nct01515228-2015-01-09`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01515228, source copy `cardio:ctgov-nct01515228-2015-01-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01515228-2015-01-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)
- Condition: Coronary Artery Disease
- Intervention (Device): Xience Prime
- Intervention (Device): Cilotax stent
- Lead sponsor: CHEOL WHAN LEE, MD, PhD.
- Lead sponsor class: OTHER
- Collaborator: CardioVascular Research Foundation, Korea
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as a collaborator: CardioVascular Research Foundation, Korea (`cardio:org-cardiovascular-research-foundation-korea`)

## Provenance

Content hash: 6518fb9d19caa075704da65ff192abdbcc6841ae8c772108c7820e8744ea81c2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
